BANNOCKBURN, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:
Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.
About Option Care Health
Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.
For Investor Inquiries:
| Mike Shapiro |
| Chief Financial Officer |
| T: (312) 940-2538 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$32.02 |
| Daily Change: | -0.25 -0.77 |
| Daily Volume: | 1,473,746 |
| Market Cap: | US$5.450B |
February 26, 2025 October 30, 2024 July 31, 2024 April 23, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
